The global Myelodysplastic Syndrome (MDS) Drugs Market size
is expected to reach USD 2.4 billion by 2022, according to a new report by
Grand View Research, Inc., exhibiting a 9.7% CAGR during the forecast period.
Factors such as strong product pipeline, rising geriatric population, and
favorable government initiatives are driving the market.
MDS is caused by mutation of one or more genes
that control development of blood cells. Patients with this condition may
present with clinical manifestations such as thrombocytopenia, neutropenia, and
anemia. Although majority of cases (over 90%) are reported in people over the
age of 60, the condition can occur at any age, more frequently in men than in
women. About 30% of MDS cases advance to acute myeloid leukemia (AML).
The immunomodulatory drug segment is expected
to retain its dominant position in the MDS drugs market due to strong sales of
Revlimid. Supported by potential approvals of luspatercept and Aranesp, the
anti-anemics drug segment is forecast to gain higher market share than
hypomethylating agents, thus contributing significantly to the overall
expansion of the market.
Developing novel drugs for the treatment of
rare subsets of MDS patients is a key challenge as the disease is highly
heterogeneous at the molecular level. In addition, morbidity issues and poor quality
of life due to incapacitating effects of the standard of care treatment
paradigms are causes of inconvenience for geriatric population.
Access Research Report of Myelodysplastic Syndrome (MDS) Drugs
Market @ https://www.grandviewresearch.com/industry-analysis/myelodysplastic-syndrome-mds-drugs-market
Further key findings from the report suggest:
- An estimated 60,000 people in U.S. are living with myelodysplastic
syndrome, with approximately 10,000-15,000 new cases being reported
annually
- U.S. dominated the global MDS drugs market with more than 48.0%
share in 2016 owing to rising disease incidence and launch of strong
pipeline candidates
- Emerging markets such as India, China, and South Korea are expected
to exhibit lucrative growth during the forecast period due to favorable
government policies, rising awareness about hematological malignancies,
increased investment, and improved healthcare infrastructure
- Immunomodulatory drugs led the drug classes with a market share of
more than 54.0% in 2016. Hypomethylating agents are projected to witness a
double-digit decline in market share due to expected patent expirations
- Celgene, Amgen, Otsuka, and Takeda are some of the key players
operating in this area; Celgene accounted for 95.2% of the market in 2016,
driven by strong sales of Revlimid and Vidaza
- Currently, there are about 45 pipeline drugs in various stages of
clinical development. Promising pipeline candidates such as Aranesp,
luspatercept, Vyxeos, guadecitabine, and pevonedistat are expected to
generate significant revenue upon launch.
Grand View Research has segmented the global
myelodysplastic syndrome (MDS) drugs/Therapeutics market based on therapeutic
class and major markets:
Myelodysplastic Syndrome (MDS) Drugs Market By Therapeutic Class Outlook
(Revenue, USD Million, 2016 - 2022)
- Hypomethylating Agents
- Immunomodulatory Drugs
- Anti-anemics
Myelodysplastic Syndrome (MDS) Drugs Market By Country Outlook (Revenue,
USD Million, 2016 - 2022)
- U.S.
- U.K.
- Germany
- Spain
- France
- Italy
- Japan
Browse more reports of this category
by Grand View Research @
https://www.grandviewresearch.com/industry/pharmaceuticals
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment